In a multivariate analysis accounting for gender, age, canonical GBM subtypes that were defined based on interpatient transcriptomic heterogeneity [36], MGMT methylation status and treatment (chemoradiation vs radiation alone); M-H versus M-La or M-Lb independently predicted shorter survivals (p= 3.0e-3 and 2.7e-13, respectively; Supplementary Table 3). The gene discussed is MGMT; the disease is glioblastoma.